Dec 22, 2023 US Food and Drugs Administration (USFDA) has approved TARPEYO (budesonide) delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. TARPEYO was first approved…

Recent Post
- Complete List of Banned Drugs in India
- Government Mandates Online CRO Registration via SUGAM Portal!
- NPPA Directs Drug Price Cuts Following Customs Duty Exemptions
- CDSCO Issues Urgent Directive for Category D FDC Manufacturers: Submit Applications by May 24, 2025
- Navigating Regulatory Changes: Gastro-Resistant & Delayed-Release Drugs as ‘New’ Under NDCT Rules 2019